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a  b  s  t  r  a  c  t
Introduction: There are few studies that carried out a descriptive and trend analysis based on
available data from the Uniﬁed Health System (SUS) between pre- and post-free dispensing
of  pharmacological treatment of rheumatoid arthritis (RA) from the perspective of the public
health system, in terms of the direct cost of the disease among adults and elderly residents
of  the State of Santa Catarina, Brazil. This study aims to characterize the direct cost of
medical and surgical procedures before and after the dispensing of drugs in this state.
Methods: This is a time series-type study with a cross-sectional survey of data from the
Hospital (SIH) and Outpatient (SIA) Information System of SUS during the period from 1996
to  2009.
Results: Between 1996 and 2009, the total expenditure for hospital- and outpatient phar-
macological treatment of rheumatoid arthritis was R$ 26,659,127.20. After the dispensing of
drug treatment by SUS a decrease of 36% in the number of hospital admissions was observed;
however, an increase of 19% in clinical procedures was noted.
Conclusion: During the observed period, a reduction in the number of hospital admissions
for  both clinical and orthopedic surgical procedures related to this disease was observed.Nevertheless, there was an increase in the cost of medical admissions.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-NDPlease cite this article in press as: Gomes RK, et al. Impact of rheumatoid arthritis in the public health system in Santa Catarina, Brazil: a
descriptive and temporal trend analysis in the period from 1996 to 2009. Rev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.07.003
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Sistema Único de Saúde
r  e  s  u  m  o
Introduc¸ão: Poucos estudos ﬁzeram uma análise descritiva e de tendência dos dados
disponíveis do Sistema Único de Saúde (SUS) entre os períodos pré e pós-dispensac¸ão gra-
tuita do tratamento medicamentoso da artrite reumatoide (AR) sob a perspectiva do sistema
público de saúde em termos de custo direto da doenc¸a entre adultos e idosos moradores do
Estado de Santa Catarina, Brasil. O presente trabalho tem o objetivo de caracterizar o custo
direto de procedimentos clínicos e cirúrgicos antes e após o fornecimento de medicamentos
no  estado.
Métodos: Estudo do tipo série temporal com levantamentos transversais entre 1996 e 2009
dos  dados do Sistema de Informac¸ão Hospitalar (SIH) e Ambulatorial (SIA) do SUS.
Resultados: Entre 1996 a 2009, o gasto total para o tratamento hospitalar e medicamen-
toso  ambulatorial da artrite reumatoide foi de R$ 26.659.127,20. Após a dispensac¸ão do
tratamento medicamentoso pelo SUS observou-se queda de 36% do número de internac¸ões
hospitalares. Entretanto notou-se um aumento de 19% nos procedimentos clínicos.
Conclusão: No período observado notou-se uma reduc¸ão do número de internac¸ões hospita-
lares tanto para procedimentos clínicos quanto cirúrgicos ortopédicos relacionadas a essa
doenc¸a.  Apesar disso, ocorreu um aumento do custo das internac¸ões clínicas.
© 2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CC
ment of SUS – DATASUS from MOH, which is freely accessible,Introduction
The World Health Organization (WHO) called the period
2000–2010 the “decade of bone and joint” due to the increasing
prevalence of rheumatic diseases and consequent socioecono-
mic  impact triggered by this situation.1 Rheumatoid arthritis
(RA) is a systemic inﬂammatory disease that affects joints,
lungs, heart and other organs.2–4 In Brazil, it is estimated
that the prevalence of RA ranges from 0.2 to 1.0% and has a
worldwide distribution.5 New options for RA treatment have
emerged in order to minimize the damage attributed to the
disease, including a faster and more  resolutive intervention,
the combination of drugs, and innovations in pharmacological
formulations.6
The interest in estimating the economic consequences and
the impact on public health stemmed by these new therapies
emerged from the relationship between the high cost of med-
ications and the direct and indirect clinical beneﬁts achieved
with treatment.7 A bibliographic search on direct costs of
rheumatoid arthritis in Brazil for our public health, held in
major databases, found a limited number of publications on
this subject.8–12
The Brazilian public health system (SUS) provides free
access to treatment of RA, such as disease-modifying
antirheumatic drugs (DMARDs) and the immunobiological
agent, tumor necrosis factor-alpha blocker (anti-TNF-alpha)
– which are high-cost drugs. Ordonnances of 2002 and 2006
from the Brazilian Ministry of Health (MOH) established that
the patient should have been in use of at least two combina-
tions of DMARDs without success as a precondition for the
provision of an anti-TNF blocker.13 More  recently, new bio-Please cite this article in press as: Gomes RK, et al. Impact of rheumato
descriptive and temporal trend analysis in the period from 1996 to 2009. R
pharmaceuticals were included in the list of drugs available
for the treatment of RA.14BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
In most of the times, the treatment of RA is carried out on
an outpatient basis. Nevertheless, studies show that the cost
generated by hospital treatment is the most signiﬁcant part
of the expenses with this disease, ranging from 55 to 68% of
the total cost, although only 10% of patients are hospitalized
annually.15 Pharmaceuticals represent a signiﬁcant expense,
especially early in the disease, when hospitalizations are less
frequent, being the second largest component of expenses
related to RA, accounting for over 25% of the total.15 Brazil-
ian studies using administrative databases covering the direct
costs of outpatient and drug treatment of RA indicate that
pharmaceuticals accounted for 68.72% of the total amount
spent.16
From a survey of available data from Hospital (SIH) and
Outpatient (SIA) Information System for the State of Santa
Catarina (SC), Brazil, we conducted a descriptive analysis of
the economic impact of RA in this state; Furthermore, we  also
evaluated the trend of costs of the disease during the years
1996–2009. Finally, we analyzed the direct costs of the disease,
from the perspective of the public health system.
Materials  and  methods
This is a time series-type study conducted to evaluate the costs
of rheumatoid arthritis among adults and elderly people liv-
ing in the State of Santa Catarina, Southern Region of Brazil,
whose survey data cover the period from 1996 to 2009. Infor-
mation on outpatient and hospital and drug treatment of RA
was obtained searching the website of the Computer Depart-id arthritis in the public health system in Santa Catarina, Brazil: a
ev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.07.003
public domain documents. Older adults of both genders and
with a primary diagnosis of rheumatoid arthritis according to
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Number of clinical procedures
Clinical procedure costs
Linear (number of clinical procedures)
Fig. 1 – Trends in the number and cost of hospital
admissions for medical procedures for patients with
rheumatoid arthritis in Santa Catarina, Brazil, between
1996 and 2009 in adults and elderly individuals. Clinical
procedure – treatment and follow-up of inﬂammatory
polyarthropathies, including diagnostic and/or therapeutic
arthrocentesis.
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Number of orthopedic surgical procedures
Orthopedic surgical procedure costs
Linear (number of orthopedic surgical procedures)
Fig. 2 – Trends in the number and cost of hospital
admissions for orthopedic surgical procedures for patients
with rheumatoid arthritis in Santa Catarina, Brazil,
between 2003 and 2009 in adults and elderly individuals.
Orthopedic procedure – knee, hip and shoulder
arthroplasty, knee synovial exploration, spine osteotomy,r  e v b r a s r e u m a t o l
he 10th revision of the International Classiﬁcation of Diseases
ICD-10), -10 M05-M06, DIAG PRINC. Column, were enlisted.
Data from the Health Information System (SIS) were
xported in its original form (.dbc ﬁle) and decompressed with
abWin program, available at DATASUS website (.dbf ﬁle). After
hat, the results were converted into Excel spreadsheets in
rder to elaborate a database, and ﬁlters for reﬁning the data
nd processing of information of interest for the study were
pplied. The information collected from SIH was: number of
ermits for hospital admissions (AIH) and total amount paid,
vailable in VAL TOT column, codes 78500036 (from 1996 to
007), and 0303090324 (from 2008 to 2009), corresponding to
linical procedures for RA, consisting of hospital treatment
nd monitoring of inﬂammatory polyarthropathies, including
iagnostic and/or therapeutic arthrocentesis. Hospitalizations
or orthopedic surgical procedures available from 2003 were:
9003124 – partial hip arthroplasty; 39016129 – total hip arthro-
lasty; 39022145 – total knee arthroplasty, 39003051 – shoulder
rthroplasty, 39010147 – knee synovial exploration, 39011020 –
pine osteotomy, 39011070 – arthroscopic lavage, and 39014053
 shoulder arthroplasty. Both codes are for procedures per-
ormed and classiﬁed in PROC REA column.
The information obtained from SIA beginning in 2002 was:
umber and total cost of permits for high-cost procedures
APAC) for the main code of this disease at APA CIDPRI column;
or age at APA IDDAAA or AP NUIDADE column; and the med-
cations were separated, both for DMARDs and for anti-TNF, in
PA TOTAL or AP VL AP column. During this period, changes
ccurred for abbreviations at age and medication columns.
he ﬁrst regulatory ordonnance (No. 865/2002) regarding drug
reatment was established in November of the same year. In
rder to balance the pre- and post-medications dispensed by
US, it was decided to split the time into two periods: the 1st
eriod from 1996 to 2002, and the 2nd period 2 between 2003
nd 2009, respectively.
This study was submitted and approved by the Human
esearch Ethics Committee of the Fundac¸ão Universidade
egional University de Blumenau (CEP-FURB) under protocol
umber 026/12.
esults
n the state of Santa Catarina between the years 1996–2009,
he total SUS expenses for hospital and outpatient medical
reatment of RA was R$26,659,127.20. The number of hospital
dmission permits was 7691, with a corresponding cost
f R$7,212,498.45, representing 27% of total costs. Of this
mount, 6000 admissions were due to clinical procedures,
ccounting for 78% of all procedures performed, with costs of
$1,144,402.08, representing only 15.9% of hospital expenses
ith the disease, when compared to orthopedic surgical
rocedures, even considering that these latter procedures
ere only booked from 2003. One can observe that before and
fter the administration of the pharmacological treatmentPlease cite this article in press as: Gomes RK, et al. Impact of rheumato
descriptive and temporal trend analysis in the period from 1996 to 2009. R
y SUS, a decreasing trend of 36% was noted in the number
f admissions due to clinical issues; this downward trend (of
8%) was also observed in orthopedic surgical procedures.
ith regard to costs, there was a 19% increase in clinicaland arthroscopic lavage.
procedures; however, this increase was offset by a decrease
of 32% of orthopedic procedures (Figs. 1 and 2).
In the outpatient scenario, the total number of high-cost
procedure permits (APAC) for the pharmacological treatment
of this disease was 40,188, at the cost of R$19,446,628.75, cor-
responding to the biggest part of the total expenditure with
rheumatoid arthritis. Only 14.7% of the total number of APACs
had been allocated to the group of anti-TNF agents, but these
drugs represented approximately 82% of the ﬁnal cost of phar-
macological treatment, that is, R$15,975,767.24 (Table 1).
Discussion
This study found that a change occurred in the proﬁle ofid arthritis in the public health system in Santa Catarina, Brazil: a
ev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.07.003
direct costs of RA in the time interval of 14 years, with a
progressive increase in costs related to permits for high-cost
procedures with reference to the pharmacological treat-
ment of RA. Notwithstanding the lower total volume for the
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Table 1 – Total number and cost (in R$) of high-cost procedure permits for rheumatoid arthritis in Santa Catarina, Brazil,
from 2003 to 2009 for adults and elderly individuals.
Year Number of high-cost procedure permits (n) Cost of high-cost procedure permits (R$)
Total number DMARD Anti-TNF Var. (%) Total cost DMARD Anti-TNF Var. (%)
2003 410 380 30 – 318,324.67 21,883.74 296,440.93 –
2004 966 894 72 2.35 468,530.65 77,823.78 390,706.87 1.47
2005 2638 2469 169 2.73 892,556.33 176,000.37 716,555.96 1.90
2006 2787 2673 114 1.05 661,825.66 149,505.46 512,320.20 0.74
2007a 43 43 0 – 3376.24 3376.24 0 –
2008 15,838 13,835 2003 – 7,707,046.64 1,564,400.13 6,142,646.51 –
2009 17,506 14,729 2777 1.10 9,394,958.56 1,477,871.79 7,917,096.77 1.21
Total 40,188 35,023 5165 19,446,628.75 3,740,861.51 15,975,767.24
tirheAnti-TNF, anti-tumour necrosis factor; DMARD, disease-modifying an
a No data available in the Outpatient Information System (SIA/SUS).
immunobiological agents dispensed, the expenses with the
pharmacological treatment of RA accounted for most of the
ﬁnancial charges for this disease. As for hospital admissions
– the second largest direct cost of the disease, the number of
admission permits by clinical procedure showed a signiﬁcant
downward trend after the free access to drug treatment by
SUS. Orthopedic surgical procedures also showed a decrease
in the number of permits and also in costs.
Medical consultation represents the lowest percentage of
the total cost of the disease, when compared to hospital and
drug costs, ranging between 10–25%.15 Similar ﬁndings in a
study conducted in Argentina in 2002 (in the prebiological
era) indicated that the admissions accounted for 73% of the
total direct cost, while drugs and outpatient procedures rep-
resented 16% and 8%, respectively.17 In a study conducted in
Germany, its authors found that over half of the medication
costs was attributed to immunobiological agents; however, the
costs associated with rheumatoid arthritis were unchanged
throughout the study period. This only occurred thanks to
the compensation of the increase in drug expenses and to the
lower hospitalization expenditures and productivity costs.18
A multicenter cross-sectional study with 1109 participants
conducted in 2000 in France established that the main rea-
son for hospitalization was the disease itself,19,20 even with a
more appropriate control of the inﬂammatory activity of RA,
demonstrably achieved with an early and aggressive treat-
ment with synthetic drugs (alone or in combination with
immunobiological agents).21,22 The decrease of 36% in the
number of hospital clinical admissions as a result of RA, found
in our study when comparing the 2nd versus 1st period, is cor-
roborated by a study based on a Southern region of Sweden
database in a period of 10 years, where a decrease of 27% and
28% for men  and women, respectively, was observed. It was
also noted a decrease of 28% in the number of hospitaliza-
tions for orthopedic causes, compared with 39% and 36% of
Swedish men  and women, respectively.22 Similarly, a cohort
study conducted in Germany comparing the costs of hospital-
izations in the periods without versus with immunobiological
agents (anti-TNF) showed a decrease, in terms of costs, from
18Please cite this article in press as: Gomes RK, et al. Impact of rheumato
descriptive and temporal trend analysis in the period from 1996 to 2009. R
29% to 13% – differently from the increase of 19% in costs in
our results for clinical admissions.
According to the authors, the direct cost for hospitalization
and medications represents something between 70% and 80%umatic drug.
of the total cost of the disease,23,24 of which the greater portion
is related to the pharmacological treatment of rheumatoid
arthritis, especially with immunobiological agents (anti-TNF),
overcoming the expenses on hospitalizations.25 A US longi-
tudinal, three-year (1999–2001) study with 7527 participants
showed that the direct cost of medications represented 66%
of the total cost, a substantially higher percentage when com-
pared with the ﬁndings of the pre-immunobiological era; and
only 25% of subjects had been receiving immunobiological
agents.26 Another 2009 study in South Korea, which used a
national database, estimated that the cost of medications was
approximately 48.6%; according to its authors, this cost is
directly related to the immunobiological therapy.27 The result
of this study points in the same direction, in that 73% of
expenditures were allocated to pharmaceuticals, even consid-
ering the use of only 14.7% of anti-TNF agents. Just as in
Brazil, other developing countries such as Colombia and Mex-
ico established that pharmaceuticals constitute the largest
component of the total direct cost.28,29
This study has some limitations inherent to the fact that
we used a secondary database for the collection of information
for its conduction, which can determine that the costs may be
higher than those reported, since many  SIS data are under-
reported or are simply lost along the consolidation ﬂow, as
occurred, for example, in 2007, with reference to the number
and total cost of the high-cost procedure permits. Moreover,
this form of data collection does not allow that one becomes
aware of the individual characteristics, for example, disease
duration, disease severity (from the milder forms, which have
a lower risk of hospitalization or of an orthopedic surgical pro-
cedure, to the most serious situations); the determination of
what were the therapeutic regimens administered throughout
the disease; the presence of comorbid conditions; and activ-
ity indices for this disease, in addition to a regular access to
health care unit providing a specialist. It is worth emphasiz-
ing that this study may have been inﬂuenced in its results,
due to the decrease in the number of hospital beds offered
by SUS in the state of Santa Catarina – from 12,750 in 2005
to 11,175 in 2009 (www.sc.ripsa.org.br; site accessed on Julyid arthritis in the public health system in Santa Catarina, Brazil: a
ev Bras Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.07.003
31, 2013). In contrast, a Brazilian study with 12,218,632 hos-
pital discharges in 1998 (data from SIH/SUS) evaluated the
existence of inconsistencies with respect to diagnostic, gen-
der, and age information. The result obtained establishes that
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he total inconsistencies for these three variables were under
.5%, i.e. a negligible error.30
Another limitation concerns the characteristics of eco-
omic evaluation studies. It should be borne in mind the
ifﬁculty of comparing costs between countries with different
conomic situations, especially among developed and devel-
ping countries, and also the monetary value of local currency,
hich undergoes changes over time, due to its exchange rate.
urthermore, the monetary data obtained through an analysis
f information systems refer to SUS charges or expenses, with
o information based on total costs for goods and services
onsumed in the healthcare service.
The knowledge of the distribution of the total direct cost of
A leads to a better use of resources; besides, this knowledge
oints to what are the areas of health care where resources can
e saved. Despite the downward trend observed in the num-
er of hospital admissions (both for clinical reasons and for
n orthopedic surgery) related to RA since the availability of
ree medical care offered by the Brazilian National Health Sys-
em, the study indicates that the ratio between the high cost
f medications and the effectiveness in reducing hospitaliza-
ions still tends to hold an unfavorable ratio. It is suggested
hat new studies for monitoring databases from health infor-
ation systems, resulting in a long-term economic analysis,
e regularly carried out, in order to recommend new possibil-
ties for reducing the direct costs of RA.
unding
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